Overview
T-cell lymphocytosis refers to an abnormal increase in T-cell numbers in the peripheral blood, often associated with various lymphoproliferative disorders and immune responses. It can be seen in conditions like cutaneous T-cell lymphoma and following CAR T-cell therapy, where immune effector cell-associated hematotoxicity may manifest 12.Diagnosis
Clinical Presentation: Elevated T-cell counts in peripheral blood smear 12.
Laboratory Tests: Complete blood count (CBC) with differential to quantify T-cell numbers 12.
Grading: For immune effector cell-associated hematotoxicity (ICAHT) post-CAR T-cell therapy, grading based on depth and duration of neutropenia:
- Early (day 0-30): Mild, Moderate, Severe
- Late (after day +30): Persistent cytopenias categorized similarly 2.Management
First-Line Treatments:
- For CAR T-cell therapy-related complications: Supportive care including infection prophylaxis, hematopoietic growth factors (e.g., G-CSF), and management of cytopenias 2.
Adjunctive Treatments:
- Specific autoimmune or inflammatory complications (e.g., pemphigoid, unstable angina) may require targeted therapies based on clinical presentation 1.Special Populations
Pediatrics: Limited specific guidance provided in the abstracts 2.
Elderly: Increased susceptibility to complications like severe cytopenias; tailored supportive care is crucial 2.
Comorbidities: Patients with pre-existing conditions may require more vigilant monitoring and management of immune effector cell-associated hematotoxicity 2.Key Recommendations
Monitor Neutropenia Closely Post-CAR T-cell Therapy: Implement detailed grading systems for early and late cytopenias to guide timely interventions (Evidence: Moderate) 2.
Utilize Supportive Care Measures: Employ prophylactic measures and hematopoietic growth factors to mitigate infectious risks and manage cytopenias (Evidence: Moderate) 2.
Evaluate for Unanticipated Adverse Events: Regularly screen for unexpected complications such as autoimmune diseases post-mogamulizumab treatment, considering their significant impact (Evidence: Weak) 1.References
1 Zhang G, Zhang H, Fu J, Cao Z. Mogamulizumab-Associated Autoimmune Diseases: Insights From FAERS Database Analysis. Cancer medicine 2024. link
2 Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P et al.. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 2023. link